According to filings with the U.S. Securities and Exchange Commission, ADARx Pharmaceuticals is raising $200,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Zhen Li played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ADARx Pharmaceuticals
ADARx Pharmaceuticals is a newly launched next-wave genetic medicine company focusing on oligonucleotide therapeutics for inhibition, degradation and base editing of mRNA transcripts. With RNA as the target of our drug discovery, we are capable of working on a wide range of diseases and are currently focusing on genetic, cardiometabolic, and central nervous system (CNS) diseases. We are driven by our mission to turn cutting-edge science into life-saving therapeutics and our desire to provide hope for patients with intractable disease. We are well-financed with backup from a group of renowned VC funds, and our brand-new laboratory is located in San Diego, California.

To learn more about ADARx Pharmaceuticals, visit http://www.adarx.com/

Contact:
Zhen Li, President and Chief Executive Officer
858-283-9472

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.